These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 21159648

  • 1. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.
    Cancer Res; 2010 Dec 15; 70(24):10288-98. PubMed ID: 21159648
    [Abstract] [Full Text] [Related]

  • 2. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.
    Mol Cell Biochem; 2011 Oct 15; 356(1-2):37-43. PubMed ID: 21755459
    [Abstract] [Full Text] [Related]

  • 3. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J, Kim SH.
    Arch Pharm Res; 2012 Aug 15; 35(8):1293-6. PubMed ID: 22941473
    [Abstract] [Full Text] [Related]

  • 4. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z.
    Int J Biol Sci; 2015 Aug 15; 11(4):411-22. PubMed ID: 25798061
    [Abstract] [Full Text] [Related]

  • 5. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A, Roolf C, Hamed M, Gladbach YS, Sender S, Konkolefski C, Knübel G, Sekora A, Fuellen G, Vollmar B, Murua Escobar H, Junghanss C.
    BMC Cancer; 2019 Mar 06; 19(1):202. PubMed ID: 30841886
    [Abstract] [Full Text] [Related]

  • 6. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN.
    Clin Cancer Res; 2013 Dec 01; 19(23):6484-94. PubMed ID: 24036851
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
    Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.
    Mol Cancer Ther; 2012 Apr 01; 11(4):994-1005. PubMed ID: 22267551
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
    Wang S, Yadav AK, Han JY, Ahn KS, Jang BC.
    Int J Mol Sci; 2022 Jun 06; 23(11):. PubMed ID: 35683032
    [Abstract] [Full Text] [Related]

  • 11. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
    Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Anderes K, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Trent K, Rice WG, Ryckman DM.
    J Med Chem; 2011 Jan 27; 54(2):635-54. PubMed ID: 21174434
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity.
    Masłyk M, Janeczko M, Martyna A, Kubiński K.
    Mol Cell Biochem; 2017 Nov 27; 435(1-2):193-196. PubMed ID: 28501934
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
    Gray GK, McFarland BC, Rowse AL, Gibson SA, Benveniste EN.
    Oncotarget; 2014 Aug 15; 5(15):6484-96. PubMed ID: 25153725
    [Abstract] [Full Text] [Related]

  • 15. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
    Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK, Ryckman DM, Anderes K, Rice WG, Drygin D.
    Cancer Lett; 2012 Sep 01; 322(1):113-8. PubMed ID: 22387988
    [Abstract] [Full Text] [Related]

  • 16. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
    Gibson SA, Yang W, Yan Z, Liu Y, Rowse AL, Weinmann AS, Qin H, Benveniste EN.
    J Immunol; 2017 Jun 01; 198(11):4244-4254. PubMed ID: 28468969
    [Abstract] [Full Text] [Related]

  • 17. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW, So KS, Kim SC, Park KM, Lee YJ, Kim SW, Choi CM, Rho JK, Choi YJ, Lee JC.
    Pancreas; 2017 Apr 01; 46(4):575-581. PubMed ID: 28196025
    [Abstract] [Full Text] [Related]

  • 18. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS, Rho JK, Choi YJ, Kim SY, Choi CM, Chun YJ, Lee JC.
    Anticancer Res; 2015 Mar 01; 35(3):1537-42. PubMed ID: 25750308
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic characterization of CK2 inhibitor CX-4945.
    Son YH, Song JS, Kim SH, Kim J.
    Arch Pharm Res; 2013 Jul 01; 36(7):840-5. PubMed ID: 23543629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.